Conference · Boston, Massachusetts
Annual Ophthalmic Drug Development Summit
Health
Key numbers
- Editions on record
- 1first in 2017
About Annual Ophthalmic Drug Development Summit
The growing disease burden and emergence of innovative new therapeutics means that the multi-billion dollar ophthalmic drug market is poised for near double digit compound growth over the next 5 years. There is enormous untapped potential for companies focusing on developing novel approaches to tackle age related macular degeneration, diabetic macular edema, glaucoma and other degenerative ocular conditions. Focussing specifically on the challenges drug developers face in the development and delivery of clinically effective ocular drugs, the 2nd Annual Ophthalmic Drug Development Summit is your opportunity to fast-track your development efforts in this space. Rather than covering early stage research or pipeline overviews, this meeting will unite leaders from Novartis, Genentech, Santen, Astellas and Spark Therapeutics to deliver granular, in-depth insights that will help you accelerate the progress of your ocular drug pipeline.
From our listing of this edition. Details may have changed since.
Editions
| Year | Dates | Where | Exhibitors | Visitors |
|---|---|---|---|---|
| 2017 | 25–27 Jul 2017 | Hyatt Regency Boston Boston, Massachusetts | — | — |
Past editions from the bvents archive (2008–2019) and organiser figures where they were published.
Questions
When is Annual Ophthalmic Drug Development Summit?
The next dates haven't been confirmed. The last edition we have on record was 25–27 Jul 2017.
Where is it held?
The last edition we have was at Hyatt Regency Boston, Boston, Massachusetts.